GDC-0587
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GDC-0587, covering 2026-04-03 to 2026-04-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer [Phase 1]